CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder

Overview of attention for article published in Frontiers in Pharmacology, March 2024

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter: 3 X users

Readers on

mendeley: 3 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 6,600 followers.

CHF6297 : a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable https://t.co/hZJB2AX22J https://t.co/MiRasmTXo7

02 Apr 2024

Reply Repost Favourite

CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder https://t.co/SiDzi1DQ3r

29 Mar 2024

Reply Repost Favourite

New Research: CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder https://t.co/uTHnv7Qu2P #pharmacology

14 Mar 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.